Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Sunnia T. Chen(Mayo Clinic), Daniel Addison(The University of Texas Southwestern Medical Center), Lindsay Rosen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tracy Wiczer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John Alan Gambril(The Ohio State University Wexner Medical Center), Patrick Ruz(The Ohio State University Wexner Medical Center), Kerry A. Rogers(The Ohio State University), Sujay Kalathoor(University of Washington), Seema A. Bhat(The Ohio State University), Michael R. Grever(The Ohio State University Wexner Medical Center), Leylah Azali(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Qiuhong Zhao(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John C. Byrd(University of Cincinnati), Marilly Palettas(The Ohio State University Wexner Medical Center), Onaopepo Kola‐Kehinde(The Ohio State University Wexner Medical Center)
Journal of Hematology & Oncology
July 14, 2022
Cited by 36


Related Papers